These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 9053848

  • 1. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site.
    de Jong R, ten Hoeve J, Heisterkamp N, Groffen J.
    Oncogene; 1997 Feb 06; 14(5):507-13. PubMed ID: 9053848
    [Abstract] [Full Text] [Related]

  • 2. Tyrosine phosphorylation of murine Crkl.
    de Jong R, Haataja L, Voncken JW, Heisterkamp N, Groffen J.
    Oncogene; 1995 Oct 19; 11(8):1469-74. PubMed ID: 7478571
    [Abstract] [Full Text] [Related]

  • 3. C3G is tyrosine-phosphorylated after integrin-mediated cell adhesion in normal but not in Bcr/Abl expressing cells.
    de Jong R, van Wijk A, Heisterkamp N, Groffen J.
    Oncogene; 1998 Nov 26; 17(21):2805-10. PubMed ID: 9840945
    [Abstract] [Full Text] [Related]

  • 4. Cellular interactions of CRKL, and SH2-SH3 adaptor protein.
    ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken JW, Heisterkamp N, Groffen J.
    Cancer Res; 1994 May 15; 54(10):2563-7. PubMed ID: 8168080
    [Abstract] [Full Text] [Related]

  • 5. Interaction of Bcr/Abl with C3G, an exchange factor for the small GTPase Rap1, through the adapter protein Crkl.
    Cho YJ, Hemmeryckx B, Groffen J, Heisterkamp N.
    Biochem Biophys Res Commun; 2005 Aug 12; 333(4):1276-83. PubMed ID: 15982636
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells.
    Tari AM, Arlinghaus R, Lopez-Berestein G.
    Biochem Biophys Res Commun; 1997 Jun 18; 235(2):383-8. PubMed ID: 9199202
    [Abstract] [Full Text] [Related]

  • 7. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
    Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J.
    Cell; 1993 Oct 08; 75(1):175-85. PubMed ID: 8402896
    [Abstract] [Full Text] [Related]

  • 8. Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase.
    Oda T, Kujovich J, Reis M, Newman B, Druker BJ.
    Oncogene; 1997 Sep 08; 15(11):1255-62. PubMed ID: 9315092
    [Abstract] [Full Text] [Related]

  • 9. Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells.
    Senechal K, Heaney C, Druker B, Sawyers CL.
    Mol Cell Biol; 1998 Sep 08; 18(9):5082-90. PubMed ID: 9710592
    [Abstract] [Full Text] [Related]

  • 10. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
    Ren SY, Xue F, Feng J, Skorski T.
    Exp Hematol; 2005 Oct 08; 33(10):1222-8. PubMed ID: 16219545
    [Abstract] [Full Text] [Related]

  • 11. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
    Salgia R, Pisick E, Sattler M, Li JL, Uemura N, Wong WK, Burky SA, Hirai H, Chen LB, Griffin JD.
    J Biol Chem; 1996 Oct 11; 271(41):25198-203. PubMed ID: 8810278
    [Abstract] [Full Text] [Related]

  • 12. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
    Gutiérrez-Berzal J, Castellano E, Martín-Encabo S, Gutiérrez-Cianca N, Hernández JM, Santos E, Guerrero C.
    Exp Cell Res; 2006 Apr 01; 312(6):938-48. PubMed ID: 16443220
    [Abstract] [Full Text] [Related]

  • 13. CRKL binding to BCR-ABL and BCR-ABL transformation.
    Kolibaba KS, Bhat A, Heaney C, Oda T, Druker BJ.
    Leuk Lymphoma; 1999 Mar 01; 33(1-2):119-26. PubMed ID: 10194128
    [Abstract] [Full Text] [Related]

  • 14. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.
    de Jong R, ten Hoeve J, Heisterkamp N, Groffen J.
    J Biol Chem; 1995 Sep 15; 270(37):21468-71. PubMed ID: 7545163
    [Abstract] [Full Text] [Related]

  • 15. Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice.
    Hemmeryckx B, van Wijk A, Reichert A, Kaartinen V, de Jong R, Pattengale PK, Gonzalez-Gomez I, Groffen J, Heisterkamp N.
    Cancer Res; 2001 Feb 15; 61(4):1398-405. PubMed ID: 11245441
    [Abstract] [Full Text] [Related]

  • 16. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
    Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD.
    Oncogene; 1996 Feb 15; 12(4):839-46. PubMed ID: 8632906
    [Abstract] [Full Text] [Related]

  • 17. Involvement of the adapter protein CRKL in integrin-mediated adhesion.
    Uemura N, Salgia R, Ewaniuk DS, Little MT, Griffin JD.
    Oncogene; 1999 Jun 03; 18(22):3343-53. PubMed ID: 10362355
    [Abstract] [Full Text] [Related]

  • 18. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.
    Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW.
    Blood; 1994 Nov 01; 84(9):2912-8. PubMed ID: 7524758
    [Abstract] [Full Text] [Related]

  • 19. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
    Hemmeryckx B, Reichert A, Watanabe M, Kaartinen V, de Jong R, Pattengale PK, Groffen J, Heisterkamp N.
    Oncogene; 2002 May 09; 21(20):3225-31. PubMed ID: 12082638
    [Abstract] [Full Text] [Related]

  • 20. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
    Uemura N, Salgia R, Li JL, Pisick E, Sattler M, Griffin JD.
    Leukemia; 1997 Mar 09; 11(3):376-85. PubMed ID: 9067577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.